First-generation somatostatin receptor ligands and pregnancy: lesson from women with acromegaly.
Magaly VialonSolange GrunenwaldCéline MoulyDelphine VezzosiAntoine BennetPhilippe J CaronPublished in: Endocrine (2020)
This review of the literature did report one malformation without being able to prove a specific link with the first-generation SRL treatment. No significant impact on maternal and fetal outcomes is related to first-generation SRL treatment in women with acromegaly. The number of pregnancies is still low and more data are necessary to conclude on the total safety of this treatment during gestation. In the meantime, based on the nonthreatening data from this review of literature, SRL treatment can be continued and/or reintroduced during pregnancy if necessary (mainly for persistent headaches) in women with acromegaly.